gamma-aminobutyric acid has been researched along with Refractory Depression in 4 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 8.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence." | 5.62 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 4.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence." | 1.62 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deligiannidis, KM | 1 |
| Clayton, AH | 1 |
| Kokane, SS | 1 |
| Armant, RJ | 1 |
| Bolaños-Guzmán, CA | 1 |
| Perrotti, LI | 1 |
| Singh, B | 1 |
| Port, JD | 1 |
| Voort, JLV | 1 |
| Coombes, BJ | 1 |
| Geske, JR | 1 |
| Lanza, IR | 1 |
| Morgan, RJ | 1 |
| Frye, MA | 1 |
| Levitt, JG | 1 |
| Kalender, G | 1 |
| O’Neill, J | 1 |
| Diaz, JP | 1 |
| Cook, IA | 1 |
| Ginder, N | 1 |
| Krantz, D | 1 |
| Minzenberg, MJ | 1 |
| Vince-Cruz, N | 1 |
| Nguyen, LD | 1 |
| Alger, JR | 1 |
| Leuchter, AF | 1 |
1 review available for gamma-aminobutyric acid and Refractory Depression
| Article | Year |
|---|---|
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Topics: Antidepressive Agents; Brain; Cholinergic Neurons; Depressive Disorder, Major; Depressive Disorder, | 2020 |
3 other studies available for gamma-aminobutyric acid and Refractory Depression
| Article | Year |
|---|---|
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; | 2023 |
A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration.
Topics: Depression; Depressive Disorder, Treatment-Resistant; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus | 2021 |
Dorsolateral prefrontal γ-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |